Highly active drug combination for treatment of hepatitis c virus
KR20200140865A
Treatment of HCV-infected patients with cirrhosis
US2018215776A1
Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus
TW201927312A
[beta]-D-2'-deoxy-2'-[alpha]-fluoro-2'-[beta]-C-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis C virus
TW201922262A
[beta]-D-2'-deoxy-2'-substituted-4'-substituted-2-substituted-N6-substituted-6-aminopurine nucleotides for the treatment of paramyxovirus and orthomyxovirus infections
KR20200106561A
2'-substituted-n6-substituted purine nucleotides for rna virus treatment
LU100724B1
Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
US2018009836A1
β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018009623A1
β-D-2'-DEOXY-2'-SUBSTITUTED-4'-SUBSTITUTED-2-SUBSTITUTED-N6-SUBSTITUTED-6-AMINOPURINE NUCLEOTIDES FOR THE TREATMENT OF PARAMYXOVIRUS AND ORTHOMYXOVIRUS INFECTIONS
